Nucleoside/nucleotide backbones for the treatment of HIV infection

Current Opinion in Investigational Drugs

Volumn 6, Issue 8, 2005, Pages 812-822

  Barreiro, Pablo ^a   Jiménez Nácher, Inmaculada ^a   García, Benito ^b   García Benayas, Teresa ^a   Rivas, Pablo ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL SEVERO OCHOA   (Spain)

Author keywords

Highly active antiretroviral therapy; HIV; Nucleosides; Nucleotides; Pharmacokinetics

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ADEFOVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; CARBOVIR; CIDOFOVIR; CLEVUDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GANCICLOVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TELBIVUDINE; TENOFOVIR; TRIFLURIDINE; UNINDEXED DRUG; VIDARABINE; ZIDOVUDINE;

AMINOACIDURIA; ANEMIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; BODY WEIGHT DISORDER; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; FANCONI RENOTUBULAR SYNDROME; GLUCOSURIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPERLIPIDEMIA; HYPOPHOSPHATEMIA; INSULIN RESISTANCE; KIDNEY TUBULE DAMAGE; LIPOATROPHY; NONHUMAN; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRESCRIPTION; REVIEW; RISK ASSESSMENT; TREATMENT FAILURE; VIROLOGY; VIRUS MUTATION; VIRUS RESISTANCE; WEIGHT REDUCTION;

ANIMALS; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; NUCLEOSIDES; NUCLEOTIDES;

EID: 23344452736     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE et al: Triple nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV infection. N Engl J Med (2004) 350(18):1850-1861.
2. Maida I, Nuñez M, Soriano V: Triple nucleoside regimens versus efavirenz. N Engl J Med (2004) 351(7):717-719.
3. Barreiro P, Garcia-Benayas T, Rendon A, Rodriguez-Novoa S, Soriano V: Combinations of nucleoside/nucleotide analogues for HIV therapy. AIDS Rev (2004) 6(4):234-243.
4. Lafeuillade A, Hittinger G, Chapadaud S: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet (2001) 357(9252):280-281.
5. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW. Pettinelli C, Dube MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L et al: Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 349(24):2293-2303.
6. Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM et al: Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 349(24):2304-2315.
7. Arribas J, Pozniak A, Gallant J, DeJesus E, Campo R, Gazzard B, Hitchock M, Lu B, McColl D, Enejosa J, Cheng A: Superior outcome for tenofovir DF, erntricitabine and efavirenz compared to fixed dose of zidovudine/lamivudine and efavirenz in antiretroviral naive patients. International Conference on Antiviral Research (2005) 18:Abs Oa202.
8. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents: AIDSinfo, Rockville, MID, USA (2005). http://www.aidsinfo.nih.gov
9. Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG: The NEAT study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr (2004) 35(1):22-32.
10. Gathe JC Jr, Ive P, Wood R, Schurmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J: SOLO: 48-Week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS (2004) 18(11):1529-1537.
11. Bartlett JA, Johnson J, Herrera G, Sosa N, Rodríguez AE, Liao Q, Griffith SK, Shaefer MS: Initial therapy with abacavir + lamivudine (ABC+3TC) combined with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001 (CLASS). International AIDS Conference (2004) 15:Abs TuPeB4544.
12. DeJesus E, Herrera G, Teofilo, E, Gerstoft J, Buendia CB, Brand JD, Brothers CH, Hernandez J, Castillo SA, Bonny T, Lanier ER et al: Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis (2004) 39(7):1038-1046.
13. Harris M, Back D, Kewn S, Jutha S, Marina R, Montaner J: Intracellular carbovir triphosphate levels in patients taking abacavir once a day. AIDS (2002) 16(8):1196-1197.
14. Drusano GL, Bilello PA, Symonds WT, Stein DS, McDowell J, Bye A, Bilello JA: Pharmacodynamics of abacavir in an in vitro hollow-fiber model system. Antimicrob Agents Chemother (2002) 46(2):464-470.
15. Yuen GJ, Lou Y, Bumgamer NF, Bishop JP, Smith GA, Otto VR, Hoelscher DD: Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother (2004) 48(1):176-182.
16. Moyle GJ, DeJesus E, Cahn P, Castillo SA, Zhao H, Gordon DN, Craig C, Scoff TR: Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: Results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr (2005) 38(4):417-425.
17. Staszewski S, Haberl A, Carlebach A, Rottmann C, Miller V, Gute P: A simple, once-daily dosing regimen for treating HIV-1 Infection in intravenous drug users. HIV Med (2000) 1(3):162-163.
18. Maggiolo F, Migliorino M, Maserati R, Pan A, Rizzi M, Provettoni G, Rizzi L, Suter F: Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther (2002) 6(4):249-253.
19. Hsieh SM, Hung CC, Lu PL, Chen MY, Chang SC: Preliminary experience of adverse drug reactions, tolerability, and efficacy of a once-daily regimen of antiretroviral combination therapy. J Acquir Immune Defic Syndr (2000) 24(3):287-288.
20. De Mendoza C, Soriano V, Pérez-Olmeda M, Rodríguez-Rosado R, González-Lahoz J: Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in HIV-Infected patients. J Hum Virol (2000) 3(6):335-340.
21. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Arici C, Ravasio L, Suter F: Once-a-day therapy for HIV infection: A controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther (2003) 8(4):339-346.
22. Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, Powderly W, Shaw AL, Mondou E, Hinkle J, Borroto-Esoda K et al: Efficacy and safety of emtricitabine vs; stavudine in combination therapy in antiretroviral-naive patients: A randomised trial. J Am Med Assoc (2004) 292(2):180-190.
23. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. J Am Med Assoc (2004) 292(2):191-201.
24. Miller MD: K65R, TAMs and tenofovir. AIDS Rev (2004) 6(1):22-33.
25. Moyle G, Sabin C, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, Leen C et al: A 48-week, randomized, open-label comparative study of tenofovir DF vs abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART. Conference on Retroviruses and Opportunistic Infections (2005) 12:Abs 44LB.
26. Gallant JE, Parish MA, Keruly JC, Moore RD: Changes in renal function associated with tenofovir disoproxil fumarate compared with nucleoside reverse transcriptase inhibitor treatment. Clin Infect Dis (2005) 40(8):1194-1198.
27. Becker S, Balu R, Fusco J: Beyond serum creatinine: Identification of renal insufficiency using glomerular filtration: Implications for clinical research and care. Conference on Retroviruses and Opportunistic Infections (2005) 12:Abs 918.
28. Van Rompay KK, Brignolo LL, Meyer DJ, Jerome C, Tarara R, Spinner A, Hamilton M, Hirst LL, Bennett DR, Canfield DR, Dearman TG et al: Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother (2004) 48(5):1469-1487.
29. Gaspar G, Monereo A, Garcia-Reyne A, de Guzman M: Fanconi syndrome and acute renal failure in a patient treated with tenofovir: A call for caution. AIDS (2004) 18(2):351-352.
30. Rifkin BS, Perazella MA: Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med (2004) 117(4):282-284.
31. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V: Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS (2004) 18(6):960-963.
32. Gathe J, Podzamczer D, Johnson M, Schwartz R, Yeh V, Travers N, Luff K, Tressler R, Brun S: Once-daily vs twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 48-Week results. Conference on Retroviruses and Opportunistic Infections (2004) 11:Abs 570.
33. Gallant J, Rodriguez A, Weinberg W: Early non-response to TDIF + ABC and 3TC: in a randomized trial compared to EFV + ABC and 3TC: ESS30009 unplanned interim analysis. Interscience Conference on Antimicrobial Agents and Chemotherapy (2003) 43:Abs1722a.
34. Landman R, Peytavin G, Descamps D, Brun-Vezinet F, Benech H, Benalisherif A, Trylesinski A, Katlama C, Girard PM, Raffi F, Yeni P et al: Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine and tenolovir: The Tonus Study. Conference on Retroviruses and Opportunistic Infections (2004) 11:Abs52.
35. Hoogewerf M, Regez RM, Schouten WE, Weigel HM, Frissen PH, Brinkman K: Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet (2003) 362(9400):1979-1980.
36. Pérez M, Terrón J, Antela A, Domingo P, Ribera E, Ocampo A, Hernandez J, Arazo P, Alvarez M, Moreno S: Virological outcome of TDF plus ABC-based regimens in previously HIV suppressed patients (24 wk preliminary results from Recover study). International Congress on Drug Therapy in HIV Infection (2004) 7:Abs P308.
37. Kearney B, Isaacson E, Sayre J, Cheng A: The pharmacokinetics of abacavir, a purine nucleoside analog, are not affected by tenofovir DF. Interscience Conference on Antimicrobial Agents and Chemotherapy (2003) 43:Abs 1615.
38. Ray AS, Olson L, Fridland A: Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother (2004) 48(4):1089-1095.
39. Hawkins T, Veikley W, St Claire R, Hey A, Guyer B, Kearney B: Intracellular pharmacokinetics of tenofovir-DP and carbovir-TP in patients receiving triple nucleoside regimens. International Workshop on Clinical Pharmacology on HIV Therapy, Rome, Italy (2004) 5:Abs 6.
40. van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, Clotet B, Staszewski S, van Eeden A, Clumeck N, Moroni M et al: A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS (2003) 17(7):987-999.
41. Lopez S, Miro O, Martinez E, Pedrol E, Rodriguez-Santiago B, Milinkovic A, Soler A, Garcia-Viejo MA, Nunes V, Casademont J, Gatell JM et al: Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir Ther (2004) 9(1):47-55.
42. Kearney BP, Flaherty JF, Shah J: Tenofovir disoproxil fumarate: Clinical pharmacology and pharmacokinetics. Clin Pharmacokinet (2004) 43(9):595-612.
43. Pecora Fulco P, Kirian MA: Effect of tenofovir on didanosine absorption in patients with HIV. Ann Pharmacother (2003) 37(9):1325-1328.
44. Martinez E, Milinkovic A, de Lazzari E, Ravasi G, Blanco J, Larrousse M, Mallolas J, Garcia F, Miro J, Gatell J: Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-Infected adults. Lancet (2004) 364(9428):65-67.
45. Palacios R, Santos J, Gonzalez M, Ruiz J, Márquez M: Reduction in body weight and CD4 lymphocyte count with simplification regimens including tenofovir and didanosine (TD). A scheme to avoid? International Congress on Drug Therapy in HIV Infection (2004) 7:Abs P19.
46. García-Benayas T, Barrios A, Sánchez-Conde M, Rendón A, R-Nóvoa S, Sánchez-Somolinos M, Maida I, Blanco F, González-Lahoz J, Soriano V: Higher risk of hyperglycemia in patients under didanosine and tenofovir-containing regimens. Conference on Retroviruses and Opportunistic Infections (2005) 12:Abs 829.
47. Robbins BL, Wilcox CK, Fidland A, Rodman JH: Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy (2003) 23(6):695-701.
48. Negredo E, Molto J, Burger D, Viciana P, Ribera E, Paredes R, Juan M, Ruiz L, Puig J, Pruvost A, Grassi J et al: Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS (2004) 18(3):459-463.
49. Barrios A, Rendon A, Negredo E, Barreiro P, Garcia-Benayas T, Labarga P, Santos J, Domingo P, Sanchez-Conde M, Maida I, Martin-Carbonero L et al: Paradoxical CD4+ T cell decline in HIV-infected patients with complete virus suppression under tenofovir plus didanosine. AIDS (2005) 19(6):569-575.
50. Arpaia E, Benveniste P, Di Cristofano A, Gu Y, Dalai I, Kelly S, Hershfield M, Pandolfi P, Roifman C, Cohen A: Mitochondrial basis for immune deficiency: Evidence from purine nucleoside phosphorylase-deficient mice. J Exp Med (2000) 191(12):2197-2208.
51. Markert M: Purine nucleoside phosphorylase deficiency. Immunodefic Rev (1991) 3(1):45-81.
52. Jemsek J, Hutcherson P, Harper E: Poor virological responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine and tenofovir DF. Conference on Retroviruses and Opportunistic Infections (2003) 11:Abs 51.
53. 3 receiving didanosine (ddl)tenfovir(TDF)efavirenz(EFV): 12 Week results from a randomized comparative trial. International Congress on Drug Therapy in HIV Infection (2004) 7:Abs PL2.5.
54. Podzamczer D, Ferrer E, Gatell JM, Niubo J, Dalmau D, Leon A, Knobel H, Polo C, Iñiguez D, Ruiz I: Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir Ther (2005) 10(1):171-177.